What does EMT stand for?

This edition includes papers on the teaching of pathology in the undergraduate curriculum, recent advances in work on primary carcinomas of the salivary glands, the intricacies of Barrett's esophagus, the concept of epithelial-mesenchymal transition in cancer invasion and metastasis, matrix metalloproteinases in neoplastic progression, new concepts of osteoarthritis, cutaneous pseudolymphoma, liquid-based cytology for cervical screening, pitfalls in the diagnosis of soft tissue tumors, sudden unexpected death in infancy, conducting the non-invasive or minimally invasive autopsy, and a histopathological view of bioterrorism.

The existence of epithelial-mesenchymal transition is an area of intense debate within the cancer research community and has been extensively reviewed elsewhere.

Initial indications of monotherapy activity for OSI-906 in NSCLC and our translational research data suggesting that compensatory signaling mechanisms and epithelial-mesenchymal transition (EMT) phenomena may make a combination of Tarceva and OSI-906 synergistically effective in the NSCLC setting provide the rationale for this clinical trial which is intended to begin in 2010.

OSI is focused on understanding the mechanisms of Epithelial-Mesenchymal Transition (EMT) as a means of developing improved cancer therapeutics.

The study also suggested that the combination of OSI-906 with Tarceva appears to be more active in epithelial tumor cells compared to those that have undergone an epithelial-mesenchymal transition (EMT).

The alliance is anchored around developing molecular targeted therapies that target the underlying mechanisms of epithelial-mesenchymal transition (EMT) in cancer, a process of emerging significance in tumor development and disease progression and the focal point of OSI's proprietary oncology research efforts.